LYMPHIR Responders Report Sustained Quality-of-Life Gains in CTCL
CRANFORD, N.J. – November 05, 2026 -- Citius Oncology (Nasdaq: CTOR) reported that 13 of 41 heavily pretreated cutaneous T-cell lymphoma (CTCL) patients with significant itch (32%; 95% CI, 18.1–48.1) achieved a clinically meaningful itch reduction on LYMPHIR (denileukin diftitox-cxdl) in the pivotal Study 302. The health-related quality of life (HRQoL) data were presented orally by Christiane Querfeld, MD, PhD, of City of Hope at the EORTC-CLTG 2026 Annual Meeting in Berlin, held October 8–10, 2026.
Responders show Skindex-29 improvement of up to 13.69 points
Among 25 responders in the primary analysis set (Stage I–III, n=69), the mean change from baseline in Skindex-29 Total Score ranged from −5.38 to −13.69 points across assessments. Lower scores indicate better quality of life. Non-responders showed slightly positive to near-zero changes.